Compare Motorola Solutions Inc (MSI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs TG Therapeutics Inc — how do they compare? Motorola Solutions Inc trades at $445.3 (market cap $74.00B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Motorola Solutions Inc is far larger — about 9.1× TG Therapeutics Inc's market cap, and Motorola Solutions Inc pays a 1.08% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 100 Days and TG Therapeutics Inc for 16 Days on average.
| MSI | TGTX | |
|---|---|---|
Market Cap | $74.00B | $8.16B |
Volume | 722,147 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $491.24 | $59.06 |
52-Week Low | $363.83 | $26.94 |
Typical Hold Time | 100 Days | 16 Days |
Enterprise Value | $82.90B | $8.37B |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSI trades at $444.18, down 0.96% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.41 surpassing the $3.85 estimate. Revenue growth has been steady, reaching $11.68 billion in 2025, and the firm recently announced a $2 billion share repurchase increase and a $139 million public safety contract in Louisiana.
The outlook remains positive with a consensus price target of $525.86, implying 18% upside, supported by a 70.59% buy rating from analysts. Risks include elevated valuation multiples, such as a P/E of 35.23, and significant investing cash outflows for acquisitions, which pressured net cash flow to -$937 million in 2025.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
